In an article entitled "Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma" Gu et al identified two distinct methylation subgroups among papillary thyroid carcinoma patients, termed the 'CpG island methylator phenotype' (CIMP) subgroup (high levels of DNA methylation) and nCIMP subgroup (low levels of DNA methylation). Authors investigated the impact of the different methylation patterns on patient's prognosis, immune profiles, epigenetic alterations and response to immune therapy or chemotherapy. They suggest that CIMP might serve as a tool for risk stratification and help to make medication guidelines for patients of different subtypes.In a paper entitled "Integrative analysis reveals novel associations between DNA methylation and the serum metabolome of adolescents with type 2 diabetes: A cross-sectional study" Agarwal et al conducted a cross-sectional integrated analysis of DNA methylation in peripheral blood mononuclear cells from adolescents with type 2 diabetes with serum metabolomic data. The objective of the study was to explore changes in the epigenetic landscape of white blood cells that might be associated with an altered serum metabolome. Authors identified differentially methylated regions in associations with a number of important metabolites in patients. Among others, metabolites include the free fatty acid receptor-1 (FFAR1), upstream transcription factor-2 (USF2), etc. Authors suggest that data may help generate new hypotheses regarding mechanisms that shape the metabolic profile.Mutations in the B-Raf proto-oncogene (BRAF) have been linked to a variety of solid tumors such as papillary thyroid carcinoma. In a paper entitled "A comparison of DP-TOF Mass Spectroscopy (MS) and Next Generation Sequencing (NGS) methods for detecting molecular mutations in thyroid nodules fine needle aspiration biopsies" authors compared DP-TOF, a DNA MS platform, and NGS methods for detecting multiple gene mutations (including BRAF V600E ) in aspiration fluid from 93 patients. Findings show that the MS method can be used as an inexpensive, accurate, and dependable initial screening method to detect gene mutations and as an adjunct to clinical diagnosis.Ewing sarcoma (EWS) is a poorly differentiated tumor with characteristic reciprocal chromosomal translocation, involving the EWS gene and one of the ETS family gene members, with high propensity for metastasis. EWS is the second most common primary tumor of bone and soft tissue in children and young people. Disruption of DNA methylation patterns represents a common feature of many forms of cancer and was proven to contribute to EWS pathogenesis. In an article entitled "Novel targeting of DNA methyltransferase activity inhibits Ewing sarcoma cell proliferation and enhances tumor cell sensitivity to DNA damaging drugs by activating the DNA damage response", Cristalli et al evaluate the efficacy of MC3343, a quinoline-based DNA methyltransferase (DNMT) inhibitor with high activity against cancer cells, including EWS. Authors demonstrate that MC3343 inhibits DNMT1 expression in EWS cells, but does not affect the methylation status of EWS cells. In addition, MC3343 slowed proliferation, induced DNA damage and cell death, and acted synergistically with other DNA damaging drugs, thereby indicating its potential use as a novel adjuvant therapeutic agent against EWS.Polycystic ovary syndrome (PCOS) is a prevalent endocrine disease in women associated with poor pregnancy outcomes. It is unknown whether sperm quality affects pregnancy outcomes of patients with PCOS. The effect of sperm DNA fragmentation on oocyte fertilization, embryonic development, and pregnancy outcomes for patients with PCOS who underwent in vitro fertilization (IVF) treatment is reported in a paper entitled "The effect of sperm DNA fragmentation on in vitro fertilization outcomes for women with polycystic ovary syndrome". Authors demonstrate that oocytes fertilized using sperm with a high DNA fragmentation index (DFI) led to a lower high-quality blastocyst formation rate but had no influence on fertilization, high-quality embryo, clinical pregnancy and miscarriage rates.The impact of female body mass index (BMI) on the DNA repair ability in oocytes after fertilization is unknown. Li et al evaluated the early embryo quality and reproductive outcomes of oocytes from overweight women when fertilized with sperm with varying degrees of DNA fragmentation. The paper, entitled "Decreased DNA repair ability: A mechanism for low early embryonic development potential of oocytes from overweight patients after fertilization in IVF cycles", is based on 1,612 patients undergoing fresh autologous IVF. Patients were divided into two groups according to maternal BMI (normal weight versus overweight) and each group was subdivided into two groups by sperm DNA fragmentation index [low (LF) versus high (HF) fragmentation]. For the normal weight group, there was no differences in embryo quality and reproductive outcomes between the LF and HF groups. However, in the overweight group, significantly lower fertilization rates, blastocyst development rates and high-quality blastocyst rates were found in the HF group, despite the similar pregnancy rates. Hence, decreased DNA repair activity in oocytes may be a possible mechanism for the low early development potential of embryos from overweight patients in IVF cycles.The diagnosis of follicular thyroid carcinoma (FTC) remains a challenge, as routine screening methods such as ultrasound could not diagnose FTC preoperatively. Yao et al performed an integrative analysis of DNA methylation and RNA array data aimed at identifying thyroid cancer-specific DNA methylation markers. The article, entitled "Integrative analysis of DNA methylation and gene expression identified follicular thyroid cancer-specific diagnostic biomarkers", was based on 14 FTC versus 16 benign thyroid lesions. Authors identified four DNA methylation sites that can be used as a potential screening tool for detection of FTC patients. Overall, the study demonstrates the potential use of methylation markers in FTC diagnosis.The feedback and feedforward regulatory mechanisms linking the endocrine systems to the DNA damage response pathway play central roles in various human disorders. The collection of papers presented in this RT further advances the understanding of intricacies of this system and how cells, tissues and organs modulate their responses and preserve homeostasis in the face of ever-changing conditions. Given their importance, endocrine system/DNA damage response biology is an intensely studied field, nevertheless many fundamental questions remain unanswered. For example, how coding and non-coding RNAs responses are coordinated by the endocrine system to avoid DNA-damage stress, what underlies the tissue-specific DNA damage responses, and how do cells modify their responses during cell division. Seeking answers to these and other questions is a fundamental research field for the near future.
13 Authors
- PA
Prasoon Agarwal
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- BA
Brandy A. Wicklow
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- AB
Allison B. Dart
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- NA
Nikho A. Hizon
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- EA
Elizabeth A.C. Sellers
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- JM
Jonathan M. McGavock
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- CP
Charlotte P. J. Talbot
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- MA
Mario A. Fonseca
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- WX
Wayne Xu
Department of Biochemistry and Medical Genetics, University of Manitoba, Canada
- JR
James R. Davie
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- MJ
Meaghan J. Jones
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
- AA
Animesh Acharjee
Institute of Cancer and Genomic Sciences, University of Birmingham, Canada
- VW
Vernon W. Dolinsky
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Research Theme of the Children’s Hospital Research Institute of Manitoba, University of Manitoba, Canada
10 Authors
- PG
Pengfei Gu
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- YZ
Yu Zeng
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- WM
Weike Ma
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- WZ
Wei Zhang
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- YL
Yu Liu
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- FG
Fengli Guo
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- XR
Xianhui Ruan
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- JC
Jiadong Chi
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- XZ
Xiangqian Zheng
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
- MG
Ming Gao
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, China
3,470 views
8 citations
14 Authors
- CC
Camilla Cristalli
Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Italy
- MC
Maria Cristina Manara
Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Italy
- SV
Sergio Valente
Department of Drug Chemistry and Technologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy
- EP
Evelin Pellegrini
Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Italy
- AB
Alberto Bavelloni
Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Italy
- AD
Alessandra De Feo
Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Italy
- WB
William Blalock
Istituto di Genetica Molecolare-Luigi Luca Cavalli Sforza, UOS Bologna, Consiglio Nazionale delle Ricerche (IGM-CNR), Italy
- ED
Elisabetta Di Bello
Department of Drug Chemistry and Technologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy
- DP
David Piñeyro
Josep Carreras Leukaemia Research Institute (IJC), Spain
- AM
Angelika Merkel
Josep Carreras Leukaemia Research Institute (IJC), Spain
- ME
Manel Esteller
Josep Carreras Leukaemia Research Institute (IJC), Spain
- OM
Oscar M. Tirado
Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Centro de Investigación Biomedica en Red Cancer (CIBERONC), Spain
- AM
Antonello Mai
Department of Drug Chemistry and Technologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy
- KS
Katia Scotlandi
Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Italy



